Background: Since the beginning of the pandemic, hundreds of trials have been performed looking at medications with the potential to be repurposed for use against COVID19. To date, no antiviral medications directed at SARS-CoV-2 have shown any convincing evidence of ...
Background: There have been lots of trials sitting on my computer desktop awaiting my review, but like many of you time has been thin from clinical work and increasing cases of COVID-19 where I work. I thought it might be ...
The Novel Coronavirus 2019, was first reported on in Wuhan, China in late December 2019. The outbreak was declared a public health emergency of international concern in January 2020 and on March 11th, 2020, the outbreak was declared a global ...
Background: There are three randomized clinical trials now published on remdesivir in the treatment of COVID-19 pneumonia (RCT 1, RCT 2, & RCT 3). The 1st trial, performed in China, was terminated early due the lack of patients to enroll ...
Background: We have covered the two previous RCTs on remdesivir on REBEL EM (RCT #1 and RCT #2). In the first trial by Wang et al , there was no statically significant improvement in clinical outcomes, but, there were trends ...
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
